Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging.
 

BACK

Pitman RK, Shin LM, Rauch SL.

VA Research Service, Manchester, NH, USA.

Rapidly evolving brain neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) are proving fruitful in exploring the pathogenesis and pathophysiology of posttraumatic stress disorder (PTSD). Structural abnormalities in PTSD found with MRI include nonspecific white matter lesions and decreased hippocampal volume. These abnormalities may reflect pretrauma vulnerability to develop PTSD, or they may be a consequence of traumatic exposure, PTSD, and/or PTSD sequelae. Functional neuroimaging symptom provocation and cognitive activation paradigms using PET measurement of regional cerebral blood flow have revealed greater activation of the amygdala and anterior paralimbic structures (which are known to be involved in processing negative emotions such as fear), greater deactivation of Broca's region (motor speech) and other nonlimbic cortical regions, and failure of activation of the cingulate cortex (which possibly plays an inhibitory role) in response to trauma-related stimuli in individuals with PTSD. Functional MRI research has shown the amygdala to be hyperresponsive to fear-related stimuli in this disorder. Research with PET suggests that cortical, notably hippocampal, metabolism is suppressed to a greater extent by pharmacologic stimulation of the noradrenergic system in persons with PTSD. The growth of knowledge concerning the anatomical and neurochemical basis of this important mental disorder will hopefully eventually lead to rational psychological and pharmacologic treatments.

J Clin Psychiatry 2001;62 Suppl 17:41-6

 

 

 



Clin Psychol Rev 2001 Aug;21(6):931-48
Posttraumatic stress disorder and traumatic brain injury: can they co-exist?

Bryant RA.

School of Psychology, University of New South Wales, Sydney, Australia. r.bryant@unsw.edu.au

The possibility that posttraumatic stress disorder (PTSD) can develop following traumatic brain injury (TBI) has been the subject of considerable debate. The traditional view has held that impaired consciousness that occurs with TBI precludes encoding of the traumatic experience, and this prevents subsequent reexperiencing symptoms. This paper critically reviews available, empirical studies on PTSD in TBI populations and suggests that these two conditions can co-exist. The various mechanisms that may mediate PTSD following TBI are discussed, and special attention is given to issues that recognize the distinctive features of PTSD following TBI. These processes include implicit processing, biologically mediated fear conditioning, and reconstruction of trauma memories. Finally implications for assessment, treatment, and forensic investigation of PTSD in TBI populations are, addressed. This review concludes that TBI populations provide a useful means by which the role of traumatic memories (and impaired memories) in posttraumatic adjustment can be studied.

J Clin Psychiatry 2001;62 Suppl 17:41-6

Biology of posttraumatic stress disorder.

Yehuda R.

Mount Sinai School of Medicine and Bronx Veterans Affairs, New York, NY, USA. rachel.yehuda@med.va.gov

Most biological findings in posttraumatic stress disorder (PTSD) are compatible with those of the chronic stress response, such as increased corticotropin-releasing factor (CRF) concentrations, catecholamine depletion within the central nervous system, and reduced hippocampal volume. However, over the last 10 years, biological observations have been made in PTSD that are different from what has been typically associated with chronic stress, notably certain hypothalamic-pituitary-adrenal (HPA) axis findings. In particular, urinary and plasma cortisol levels are considerably lower in PTSD patients than in non-PTSD trauma survivors and normal controls. Furthermore, the circadian pattern of cortisol release from the adrenal glands follows a greater dynamic range in PTSD than in patients with major depression or in normal controls. The reduction in cortisol levels results from an enhanced negative feedback by cortisol, which is secondary to an increased sensitivity of glucocorticoid receptors in target tissues. This HPA axis alteration contrasts with the well-known chronic stress cascade in which CRF release results in erosion of negative feedback and down-regulation of glucocorticoid receptors. Sensitization of the HPA axis is consistent with the clinical picture of hyperreactivity and hyperresponsiveness in PTSD.

 


Home | Our Center | Dr. Braciszewski | F.A.Q. | Discussions | News | Links | Email Us

Web Site Design and Maintained by: Web Weavers, Inc.
All Rights Reserved

Web Site Links Disclaimer: At certain places in this site, links to other web sites can be accessed. Links to other Internet sites are provided as a convenience only. These sites contain information created, published, and maintained by organizations independent of AARC,Inc..
We do not endorse, approve, certify or control these web sites or the opinions, information, products or services contained therein, and do not guarantee the accuracy, completeness, efficacy or timeliness of information located therein, or at any link contained in a linked site. Internet locations change frequently, so many of the links provided on this web site may no longer access the external web sites listed herein.

No Medical Advice: The information posted here is not intended to be and should not be considered medical advice, as it is designed to support, not replace, the relationship that exists between a patient and his or her existing healthcare provider. It is not a substitute for the professional medical advice, diagnosis or treatment provided by your physician, other qualified health provider or any information included by the manufacturer with or on any product. Never disregard professional medical advice or delay in seeking it because of something you have read on or through the AARC web site. If you think you may have a medical emergency, call your doctor or 911 immediately.
YOU SHOULD ALWAYS CONSULT A PHYSICIAN OR OTHER HEALTHCARE PROVIDER OF YOUR OWN CHOICE AND CAREFULLY READ ALL PACKAGING AND OTHER INFORMATION PROVIDED BY THE MANUFACTURER OF ANY MEDICAL PRODUCTS OR DEVICES BEFORE USING THEM.